Cheryl Cohen
Directeur/Membre du Conseil chez CELLDEX THERAPEUTICS, INC.
Fortune : 1 M $ au 31/05/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Joseph H. Gardner | M | 68 |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 17 ans |
| Barry Simon | M | 59 | 17 ans | |
| John McBride | M | 72 |
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 10 ans |
| Anthony Marucci | M | 62 | 41 ans | |
| Sam Martin | M | 53 | 15 ans | |
| Patrick Soon-Shiong | M | 71 | 10 ans | |
| Sarah Cavanaugh | F | 49 | 12 ans | |
| Richard Adcock | M | 55 | 4 ans | |
| Mitchell Brigell | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 7 ans |
| Karen Shoos | F | 70 | 23 ans | |
| Stephen Pakola | M | 55 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 9 ans |
| Herbert Conrad | M | 91 | 16 ans | |
| David-Alexandre Gros | M | 51 | 4 ans | |
| Kevin G. Peters | M | 67 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 11 ans |
| John Brennan | M | 67 | 3 ans | |
| Sarah Singleton | F | - | 4 ans | |
| Rita Jain | M | 62 | 1 ans | |
| Linda Maxwell | M | 50 | 3 ans | |
| Jason R. Liljestrom | M | 41 | - | |
| Keith Brownlie | M | 71 | 7 ans | |
| Harry Penner | M | 78 | 27 ans | |
| Tibor Keler | M | 65 | 41 ans | |
| James Marino | M | 74 | 7 ans | |
| Wesley Clark | M | 78 | 3 ans | |
| Caley Castelein | M | 53 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 7 ans |
| Keith Katkin | M | 52 | 7 ans | |
| Christobel Selecky | F | 69 | 3 ans | |
| Garry Neil | M | 70 | 2 ans | |
| Michael Blaszyk | M | 71 | 9 ans | |
| Jason Sausser | M | - | 2 ans | |
| Ronald Pepin | M | 68 | 13 ans | |
| Eric Deng | M | - | 3 ans | |
| Chris Kontos | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Dietmar Vestweber | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Helen Luu | F | - | 3 ans | |
| Freddy Jimenez | M | 55 | 8 ans | |
| David Sachs | M | 46 | 3 ans | |
| Leonard Sender | M | - | 4 ans | |
| Eugene Park | M | - | 3 ans | |
| Regan Lauer | F | 55 | 3 ans | |
| Margo Heath-Chiozzi | M | 67 | 7 ans | |
| Enrique Dilone | M | 57 | 1 ans | |
| John Lee | M | 56 | 5 ans | |
| Elizabeth Crowley | F | 52 | 15 ans | |
| Anne Frese | F | - | 2 ans | |
| Diane Young | M | 68 | 5 ans | |
| Richard Wright | M | 60 | 12 ans | |
| Sandeep K. Reddy | M | - | 4 ans | |
| Anupam Dalal | M | 52 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Hans Klingemann | M | 74 | - | |
| Caroline Ruiz | F | - | 2 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Jodie Morrison | F | 48 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 12 ans |
| Michael Rogers | M | 64 | 2 ans | |
| Muneer Satter | M | 63 |
Vital Therapies, Inc.
 Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 8 ans |
| Regina Marek | F | 55 | 3 ans | |
| Jon S. Kuwahara | M | 59 | 4 ans | |
| Dawn Svoronos | F | 70 | 3 ans | |
| Gregory Flesher | M | 54 | 3 ans | |
| Daniel Vitt | M | 55 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | - |
| Michael V. Swanson | M | 69 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 6 ans |
| Terence E. Winters | M | 82 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 14 ans |
| Steven Prelack | M | 66 | 4 ans | |
| Christine Ocampo | F | 51 | - | |
| Jennifer J. Rhodes | F | 53 | 3 ans | |
| Faheem Hasnain | M | 65 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 3 ans |
| Jean-Jacques Bienaimé | M | 70 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 5 ans |
| Douglas Godshall | M | 59 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 5 ans |
| Sujay Kango | M | 60 | 2 ans | |
| J. Michael Millis | M | 65 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 12 ans |
| Erez Chimovits | M | 60 | 3 ans | |
| Manfred Gröppel | M | 55 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | - |
| Russell Cox | M | 60 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 1 ans |
| Lowell E. Sears | M | 73 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 6 ans |
| Joseph Scodari | M | 71 |
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 3 ans |
| Ofir Moreno | M | - | 12 ans | |
| Catherine Turkel | M | 63 | 3 ans | |
| Kevan E. Clemens | M | 80 | 7 ans | |
| Dominic Piscitelli | M | 50 | 5 ans | |
| Pravin Dugel | M | 60 | 4 ans | |
| Lee Kalowski | M | 43 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 2 ans |
| Tony Vernon | M | 69 |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 3 ans |
| Rohan Palekar | M | 58 |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 10 ans |
| Wendy Yarno | F | 68 | 3 ans | |
| Gary Lyons | M | 73 | 6 ans | |
| John Dunn | M | 72 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 5 ans |
| Gregory Bailey | M | 68 | 7 ans | |
| Louis Yu | M | 73 |
Solvay Pharmaceuticals, Inc.
 Solvay Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Solvay Pharmaceuticals, Inc manufactures pharmaceutical products. The company produces therapies for cardi-metabolic, gastroenterological, and neurological disorders. Its brands include Androgel, Klonopin, and ACEON drugs. Solvay Pharmaceuticals was founded by Ernest Solvay in 1863 and is located in Marietta, GA. | 3 ans |
| Richard A. Bierly | M | 68 | 2 ans | |
| Benjamin S. Levin | M | 46 | 12 ans | |
| Kathryn Falberg | F | 63 | 3 ans | |
| Errol Halperin | M | 83 |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | 6 ans |
| Stephen Hoffman | M | 70 | 2 ans | |
| Timothy Barberich | M | 76 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 8 ans |
| Christian Schneider | M | - |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 5 ans |
| Glenn Mattes | M | 68 |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 4 ans |
| Dominic Caruso | M | 66 |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 14 ans |
| David P. Holveck | M | 79 |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 16 ans |
| Sally D. Bolmer | M | - |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 14 ans |
| Neal Fowler | M | 62 |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | 2 ans |
| Rick Anderson | M | 63 |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 100 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Cheryl Cohen
- Réseau Personnel
